Navigation Links
AFFiRiS AG: Vaccination Against Hypertension is Development Project No. 4 and has Already Been Awarded an FFG Grant of up to EUR 1.2 Million
Date:2/25/2010

he company's own AFFITOME(R) technology. However, for the first time it is now being used against a human hormone. The reason for this announcement is the gratifying approval of significant development funds by the Austrian Research Promotion Agency, FFG.

Today, Viennese biotech company AFFiRiS AG announced the start of a new program to develop a vaccine against hypertension. This means that there are now four of the company's current seven development projects in the public domain. The specific reason for the "outing" of project no. 4 was the approval of public research promotion funds by the FFG. The vaccine is targeting angiotensin II, a peptide hormone that can cause narrowing of the blood vessels and thereby hypertension.

Dr. Walter Schmidt, CEO of AFFiRiS AG comments on the company's development pipeline: "With projects in seven different indications at the moment, AFFiRiS AG has achieved a broad diversification of potential development risks. While building up this pipeline we were consequently guided by our strategic focus, which is targeting disease areas with very large numbers of patients and lack of optimal therapies. We believe that systematic risk distribution, together with a focus on indications with a high market potential is the key for substantial success of a biotechnology company. The early VC investment by MIG Fonds AG, Munich, was of substancial importance for the establishment of our strong development pipeline. Our first licensing agreement on our Alzhe
'/>"/>

SOURCE AFFiRiS AG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. AFFiRiS - MIG-Fonds Increases Investment by Euro 3 Million
2. GlaxoSmithKline and AFFiRiS Sign an Exclusive Licence and Option Agreement for Therapeutic Alzheimers Disease Candidate Vaccines
3. AFFiRiS AG: Atherosclerosis Vaccine Development Receives EU Support
4. AFFiRiS AG: 1st Place in Venture Capital & Private Equity Awards for MIG Fonds and AFFiRiS
5. AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimers Vaccine Candidate AD02 into Clinical Phase II Testing
6. Persistent Vaccination Effect of GRAZAX(R) After Completion of Treatment
7. New study indicates smallpox vaccination effective for decades
8. New study indicates smallpox vaccination effective for decades
9. Insect cells provide the key to alternative swine flu vaccination
10. Shareholder Class Action Filed Against GPC Biotech AG by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
11. FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Sept. 22, 2014 Research and Markets ... and Chinese Microcrystalline Cellulose Industry Report 2014" report ... Chinese Microcrystalline Cellulose Industry Report 2014 is a professional ... global microcrystalline cellulose industry with a focus on the ... overview of the industry including definitions, classifications, applications and ...
(Date:9/22/2014)... TORONTO , Sept. 22, 2014 /PRNewswire/ ... today announced that it has entered into a ... which UHN,s Centre for Molecular Design and Preformulations ... project.  The goal of the project is to ... Company,s proprietary buccal insulin spray product, thereby reducing ...
(Date:9/22/2014)... Washington, D.C (PRWEB) September 22, 2014 ... the top privately held biotechnology companies of 2014. ... of companies before selecting this year’s winners. Those ... private biotechnology companies in the industry. , ... a new group of Fierce 15 companies," said Carroll. ...
(Date:9/22/2014)... , September 22, 2014 ... on a mixed note as the Dow Jones Industrial ... Composite closed at 4,579.79, down 0.30%. The S&P 500 ... trading session, six out of ten sectors finished on ... Index ended the day at 751.48, up 0.10%, with ...
Breaking Biology Technology:Global and Chinese Microcrystalline Cellulose Industry Report 2014 2Generex Collaborates with University Health Network for Buccal Insulin Project 2Generex Collaborates with University Health Network for Buccal Insulin Project 3Generex Collaborates with University Health Network for Buccal Insulin Project 4FierceBiotech Announces Annual “Fierce 15” Winners of 2014 2Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 2Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 3Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 4Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 5
... PRINCETON, N.J., May 1 Ranbaxy Pharmaceuticals ... voluntary recall of all lots of Nitrofurantoin (Monohydrate/Macrocrystals) Capsules, ... U.S. Although certain lots of the product were ... laboratory specifications, Ranbaxy decided to recall all the lots, ...
... May 1 /PRNewswire-Asia/ -- Yongye Biotechnology International, Inc. (OTC ... distributor of plant and animal nutrient products located in ... of the independently owned Yongye branded retail stores in ... day sales.A Yongye branded retail store in Qianjiang City ...
... 1 Tigris Pharmaceuticals, Inc., a privately held drug ... a Phase I clinical trial of GGTI-2418. GGTI-2418 ... I) that induces apoptosis by downregulating several pivotal oncogenic ... by Dr. Peter O,Dwyer, Professor of Medicine at the ...
Cached Biology Technology:Yongye Biotechnology Distributor has Record Breaking Single Store Sales Day 2Yongye Biotechnology Distributor has Record Breaking Single Store Sales Day 3First Patient Dosed in Phase I Clinical Trial of Tigris Pharmaceuticals' GGTI-2418 2First Patient Dosed in Phase I Clinical Trial of Tigris Pharmaceuticals' GGTI-2418 3
(Date:9/19/2014)... will study multifunctional and specialized spinal cord nerve ... Science Foundation grant in the amount of $680,000 ... in the Department of Biology, OU College of ... between the multifunctional and specialized spinal cord nerve ... what connections they make. Berkowitz will collaborate ...
(Date:9/19/2014)... Inc. (Nasdaq: NXTD and NXTDW) ("Nxt-ID" or the ... updates the "Wocket in Your Pocket" celebrity ad campaign, featuring former ... classes, Vinny Pazienza (PAZ). , ... actor Ciaran Hinds and Sons of Anarchy ... have been cast in Bleed for This . ...
(Date:9/18/2014)... A new GSA Bulletin study uses ... Rio Puerco and Chaco Wash in northern New Mexico, ... salt cedar and willow, investigators were able to precisely ... They then combined this data with aerial imagery, LiDAR, ... of these arroyos. , Arroyos are deep, oversized channels ...
Breaking Biology News(10 mins):NXT-ID's Vinny Paz Celebrity Ad Wocket Update: Katey Sagal and Ciaran Hinds Attached to His Upcoming Movie 2NXT-ID's Vinny Paz Celebrity Ad Wocket Update: Katey Sagal and Ciaran Hinds Attached to His Upcoming Movie 3Tree rings and arroyos 2Tree rings and arroyos 3Tree rings and arroyos 4Tree rings and arroyos 5Tree rings and arroyos 6Tree rings and arroyos 7
... and biological aspects of cellular self-organization are well-studied; less ... how their behavior and communication are affected by ... the University of California San Diego, in a paper ... of the National Academy of Sciences, have begun ...
... Japanese researchers were awarded the 2008 SNM Wagner-Torizuka ... States through 2010 as part of the two-year ... Medical College, undertaking a fellowship at Johns Hopkins ... the University of Washington, Seattle; Ryo Nakazato, Toho ...
... has clearly illustrated, the top priority for the next ... Believing that expanding the nation,s commitment to basic ... the next President can take to ensure our long-term ... questions (attached) to the moderator of tomorrow,s presidential debate. ...
Cached Biology News:UC San Diego bioengineers fill holes in science of cellular self-organization 22008 SNM Wagner-Torizuka Fellowships announced 22008 SNM Wagner-Torizuka Fellowships announced 3The Science Coalition's '10 questions' for the presidential debate 2
... of 3 siRNAs specifically targeted to your ... product. The siTrio reagent guarantees you get ... gene when used under standard conditions (100 ... optimal transfection with one of B-Bridges controls). ...
... a cocktail of 3 siRNAs specifically targeted ... most popular product. The siTrio reagent guarantees ... your target gene when used under standard ... confirmation of optimal transfection with one of ...
... has improved stability and convenience from the former ... has overcome this problem but also produced some ... the formulation of HRP conjugated antibody from lyophilized ... change, the stability of the conjugate has improved ...
... suitable for a wide range of molecular ... Pulsed Field Gel Electrophoresis (PFGE). Due to ... Multi ABgarose can effectively separate large DNA ... turn means reduced band diffusion, a problem ...
Biology Products: